Brief: Hutchmed (China) Says NDA For Fanregratinib Accepted With Priority Review In China

HUTCHMED (China)

29/12/2025 10:29

Dec 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK:

NDA FOR FANREGRATINIB ACCEPTED WITH PRIORITY REVIEW IN CHINA

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))